Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire11-12

Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482765512?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QgRx4xT.lDlZwhWdU9QtvQ--~B/aD01MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6a300ee43d00bd4b0b0022a6aa54de1d","is_english":true,"pubTime":"2024-11-12 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482765512","market":"us","top_or_hot":-1,"title":"Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update","media":"GlobeNewswire","content":"<div>\n<p>Revenues increased 17% compared to the previous quarter ended June 30, 2024\nStrengthened balance sheet is expected to provide sufficient cash runway through June 2026 \nCompleted a $20.6 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/beyond-air-reports-fiscal-second-210500605.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/beyond-air-reports-fiscal-second-210500605.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenues increased 17% compared to the previous quarter ended June 30, 2024\nStrengthened balance sheet is expected to provide sufficient cash runway through June 2026 \nCompleted a $20.6 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/beyond-air-reports-fiscal-second-210500605.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://finance.yahoo.com/news/beyond-air-reports-fiscal-second-210500605.html","article_id":"2482765512","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QgRx4xT.lDlZwhWdU9QtvQ--~B/aD01MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6a300ee43d00bd4b0b0022a6aa54de1d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482765512","pubTimestamp":1731359100,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenues increased 17% compared to the previous quarter ended June 30, 2024. Strengthened balance sheet is expected to provide sufficient cash runway through June 2026. Completed a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders. Retired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group. Conference call scheduled for 4:30 p.m. ET today, November 11th. Lisi added: “Our executive team and board of directors have taken decisive actions this year to enhance the Company’s financial health and commercial execution as we continue accelerating our revenue growth. We recently implemented a capital conservation strategy to preserve cash, executed a series of financial transactions that increased our capital resources and eliminated approximately $12 million in debt-related payments through mid-2026. We are confident that these strategic initiatives, in con","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备","WRD":"文远知行","XAIR":"BEYOND AIR INC","BK4231":"零售房地产信托","BK4187":"航天航空与国防","BK4080":"零售业房地产投资信托","SITC":"SITE Centers Corp.","AIRI":"Air Industries Group","BK4588":"碎股","BK4178":"家庭装饰零售"},"translate_title":"超越®航空报告2025财年第二季度财务业绩并提供公司最新动态","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIRI":1,"SITC":1,"WRD":1,"XAIR":0.9},"content_text":"Revenues increased 17% compared to the previous quarter ended June 30, 2024\nStrengthened balance sheet is expected to provide sufficient cash runway through June 2026 \nCompleted a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders\nRetired $17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group\nConference call scheduled for 4:30 p.m. ET today, November 11th\nGARDEN CITY, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced its financial results for the fiscal second quarter ended September 30, 2024, and provided a corporate update.\n“Our commercial strategy continued to drive results throughout the quarter with our total number of customers increasing by over 60%,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “We believe this is just the beginning of a pivotal year for our Company as we leverage our expanding network of reference customers that have implemented LungFit PH in their hospitals. We have a strong foundation of customer success stories that speak to the cost savings, workflow improvements and additional value our technology delivers in a real-world setting, compared to traditional cylinder-based systems. In addition, since joining our team four months ago, our new Chief Commercial Officer, David Webster, has won key partners to rapidly accelerate our topline growth, including TrillaMed, Healthcare Links and Business Asia Consultants, among others, resetting our commercial strategy and reorganizing our sales, marketing and support teams.”\nLisi added: “Our executive team and board of directors have taken decisive actions this year to enhance the Company’s financial health and commercial execution as we continue accelerating our revenue growth. We recently implemented a capital conservation strategy to preserve cash, executed a series of financial transactions that increased our capital resources and eliminated approximately $12 million in debt-related payments through mid-2026. We are confident that these strategic initiatives, in conjunction with projected revenue growth, will extend our cash runway to support our current operating plans through June 2026.”\nRecent Commercial Execution, Portfolio Highlights and Upcoming Milestones\nLungFit® PH \n\nCommercial Execution\n\nIncreased commercial demand for LungFit PH, as evidenced by: \n    \nA 17% increase in revenue for the quarter ended September 30, 2024, compared with the previous quarter ended June 30, 2024\nThe number of hospital contracts increased by 60% over the course of the second fiscal quarter of 2025\nAnnounced the U.S. Naval Hospital Guam has deployed the LungFit PH system in its mission to provide top-tier neonatal care\nAnnualized contracted revenue was $3.5 million on October 1, 2024; with an additional four hospitals slated to start later in fiscal 3Q 2025 further increasing the annualized run rate\n \nEntered a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting firm, that will focus on expanding access to the LungFit® PH system by streamlining entry into Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) across the United States\nPartnered with Business Asia Consultants, Inc. - an international sales, marketing and business development consulting company with extensive experience in Europe, the Pacific Rim and Latin America - to help accelerate the global expansion of the LungFit PH\nPartnered with TrillaMed, a premier provider of medical supplies and technologies to government and healthcare systems globally, to bring LungFit PH to the U.S. Veterans Administration and Department of Defense hospitals\n \nPipeline Highlights\n\nCardiac surgery PMA supplement review ongoing at FDA \n    \nCurrently no FDA approved nitric oxide system is labeled for cardiac surgery\nApproval would increase LungFit PH’s rate of market penetration and support long-term revenue growth\n \nA decision on CE Mark for LungFit PH in Europe expected before year-end 2024\nLungFit PH transport-ready PMA supplement submission to FDA anticipated in CY 1Q 2025\n \n\nBeyond Cancer - Solid Tumor Program\n\nClinical Development Execution\n\nUltra-high concentration Nitric Oxide (UNO) therapy is in an ongoing Phase 1a trial evaluating advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors \n    \nPromising preclinical data presented in two posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 showed the efficacy of low volume (LV) UNO – less than 10% of the UNO dose that showed an acceptable safety profile in the ongoing Phase 1a study – when combined with immune checkpoint inhibitors. In a study using MAT B III tumor-bearing rats, LV UNO combined with anti-rPD-L1 doubled the tumor growth inhibition rate and led to improved survival outcomes compared to anti-rPD-L1 alone. Based on these data, the Beyond Cancer team believes LV UNO may positively influence PD-1 progressors and broaden the pool of patients who could benefit from immunotherapy, including those previously ineligible for treatment\nUpon clearance from regulators in Israel, expected shortly, a Phase 1b trial is planned to enroll up to 20 subjects with prior exposure to anti-PD-1 antibody that have either progressed, not achieved a response, or have prolonged stable disease (≥ 12 weeks) on single agent anti-PD-1 without radiographic evidence of continued tumor reduction. Subjects enrolled in the Phase 1b trial will be treated with UNO + anti-PD-1 combination\n \n \nBeyond Cancer intends to seek additional capital to perform human studies in addition to the planned Phase Ib trial\n\nRecent Corporate Updates \n\nCompleted a private placement offering for gross proceeds of approximately $20.6 million, which included participation by multiple healthcare-focused institutional funds, as well as Company insiders\nRetired $17.5 million in Avenue Capital debt, eliminating approximately $12 million in debt-related payments through June 2026. In addition, Avenue Capital invested $3.35 million in the private placement offering\nEntered into an $11.5 million loan agreement with an insider-led investor group, which utilizes an 8% royalty on net sales beginning in July 2026 to repay the loan. The royalty would cease upon complete loan repayment\n\nFinancial Results for the Fiscal Second Quarter Ended September 30, 2024\nRevenues for the fiscal quarter ended September 30, 2024 were $0.8 million compared to $0.2 million for the fiscal quarter ended September 30, 2023 and $0.7 million for the previous quarter ended June 30, 2024. Cost of revenue of $1.9 million was recognized for the three months ended September 30, 2024, compared to $0.4 million for the three months ended September 30, 2023. Cost of revenue exceeded revenue primarily driven by depreciation of LungFit devices and one-time upgrade costs to systems.\nResearch and development expenses for the three months ended September 30, 2024, were $4.6 million as compared to $7.1 million for the three months ended September 30, 2023. The decrease of $2.5 million was primarily attributed to a decrease in salaries, stock-based compensation and pre-clinical studies expenses.\nSelling, general and administrative expenses for the three months ended September 30, 2024 and September 30, 2023 were $7.2 million and $10.2 million, respectively. The decrease of $3.0 million was attributed primarily to a reduction in stock-based compensation cost.\nOther income and expense for the three months ended September 30, 2024 was a loss of $1.2 million compared to a gain of $0.1 million for the three months ended September 30, 2023. The decrease of $1.3 million was mainly due to the impact of the partial retirement of the Avenue Capital debt. Cash burn in the fiscal quarter ended September 30, 2024, excluding financing and one-time items was $11.5 million.\nAs of September 30, 2024, the Company reported cash, cash equivalents, and marketable securities of $28.4 million, and total debt outstanding of $12.5 million. Due to the timing of cash settlements associated with the aforementioned financial transactions that were completed subsequent to September 30, 2024, pro forma cash was $18.5 million, and pro forma outstanding debt was $11.5 million. The Company’s strengthened balance sheet, along with our cash conservation strategy and anticipated revenue growth, is expected to provide sufficient cash runway to support current operating plans through June 2026.\nConference Call & Webcast\n\n\n\nMonday, November 11th @ 4:30 PM ET\n\n\nDomestic:\n1-877-407-0784\n\n\nInternational:\n1-201-689-8560\n\n\nConference ID:\n13749670\n\n\nWebcast:\nA webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call.\n\n\n\nAbout Beyond Air®, Inc.Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.\nAbout LungFit®*Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.\n* Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.\nAbout PPHNPersistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.\nAbout Beyond Cancer, Ltd.Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in patients with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols.\nFor more information, visit www.beyondcancer.com.\nForward Looking StatementsThis press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.\nCONTACTS:Investor Relations contactsCorey Davis, Ph.D.LifeSci Advisors, LLCCdavis@lifesciadvisors.com(212) 915-2577\n\n\n\n \n\n\n \n\n\nBEYOND AIR, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(amounts in thousands, except share and per share data)\n\n\n \n\n\n \nSeptember 30, 2024\n \n \nMarch 31, 2024\n \n\n\n \n(Unaudited)\n \n \n \n \n\n\nASSETS\n \n \n \n \n \n \n \n\n\nCurrent assets\n \n \n \n \n \n \n \n\n\nCash and cash equivalents\n$\n28,447\n \n \n$\n11,378\n \n\n\nMarketable securities\n \n-\n \n \n \n23,090\n \n\n\nRestricted cash\n \n230\n \n \n \n230\n \n\n\nAccounts receivable\n \n556\n \n \n \n319\n \n\n\nInventory, net\n \n2,527\n \n \n \n2,127\n \n\n\nOther current assets and prepaid expenses\n \n6,275\n \n \n \n6,792\n \n\n\nTotal current assets\n \n38,036\n \n \n \n43,936\n \n\n\nLicensed right to use technology\n \n1,325\n \n \n \n1,427\n \n\n\nRight-of-use lease assets\n \n1,897\n \n \n \n2,121\n \n\n\nProperty and equipment, net\n \n11,648\n \n \n \n9,364\n \n\n\nOther assets\n \n105\n \n \n \n113\n \n\n\nTOTAL ASSETS\n$\n53,010\n \n \n$\n56,961\n \n\n\n \n \n \n \n \n \n \n \n\n\nLIABILITIES AND STOCKHOLDERS’ EQUITY\n \n \n \n \n \n \n \n\n\nCurrent liabilities\n \n \n \n \n \n \n \n\n\nAccounts payable\n$\n1,490\n \n \n$\n1,948\n \n\n\nAccrued expenses and other current liabilities\n \n4,470\n \n \n \n8,402\n \n\n\nOperating lease liability, current portion\n \n381\n \n \n \n418\n \n\n\nLoans payable, current portion\n \n258\n \n \n \n800\n \n\n\nTotal current liabilities\n \n6,599\n \n \n \n11,567\n \n\n\n \n \n \n \n \n \n \n \n\n\nOperating lease liability, net\n \n1,690\n \n \n \n1,898\n \n\n\nLong-term debt, net\n \n10,940\n \n \n \n14,721\n \n\n\nLong term liability, related party\n \n4,427\n \n \n \n-\n \n\n\nWarrant Liability\n \n60\n \n \n \n275\n \n\n\nDerivative liability\n \n-\n \n \n \n1,314\n \n\n\nTotal liabilities\n \n23,716\n \n \n \n29,775\n \n\n\n \n \n \n \n \n \n \n \n\n\nStockholders’ equity\n \n \n \n \n \n \n \n\n\nPreferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding\n \n-\n \n \n \n-\n \n\n\nCommon Stock, $0.0001 par value per share: 100,000,000 shares authorized, 72,187,636 and 45,900,821 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively\n \n7\n \n \n \n5\n \n\n\nTreasury stock\n \n(25\n)\n \n \n(25\n)\n\n\nAdditional paid-in capital\n \n293,391\n \n \n \n264,780\n \n\n\nAccumulated deficit\n \n(265,255\n)\n \n \n(239,697\n)\n\n\nAccumulated other comprehensive income (loss)\n \n9\n \n \n \n(15\n)\n\n\nTotal stockholders’ equity attributable to Beyond Air, Inc\n \n28,127\n \n \n \n25,048\n \n\n\nNon-controlling interest\n \n1,167\n \n \n \n2,138\n \n\n\nTotal equity\n \n29,294\n \n \n \n27,186\n \n\n\nTOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY\n$\n53,010\n \n \n$\n56,961\n \n\n\n\n\n\n\n \n\n\nBEYOND AIR, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(amounts in thousands, except share and per share data)(UNAUDITED)\n\n\n            \n\n\n \nFor the Three Months Ended\n \n \nFor the Six Months Ended\n \n\n\n \nSeptember 30,\n \n \nSeptember 30,\n \n\n\n \n2024\n \n \n2023\n \n \n2024\n \n \n2023\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n\n\nRevenues\n$\n798\n \n \n$\n239\n \n \n$\n1,481\n \n \n$\n298\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nCost of revenues\n \n1,882\n \n \n \n432\n \n \n \n2,897\n \n \n \n735\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nGross loss\n \n(1,084\n)\n \n \n(193\n)\n \n \n(1,416\n)\n \n \n(437\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nOperating expenses:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nResearch and development\n \n(4,585\n)\n \n \n(7,130\n)\n \n \n(10,594\n)\n \n \n(11,826\n)\n\n\nSelling, general and administrative\n \n(7,163\n)\n \n \n(10,211\n)\n \n \n(14,402\n)\n \n \n(21,147\n)\n\n\nTotal Operating expenses\n \n(11,748\n)\n \n \n(17,342\n)\n \n \n(24,995\n)\n \n \n(32,972\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nLoss from Operations\n \n(12,833\n)\n \n \n(17,535\n)\n \n \n(26,412\n)\n \n \n(33,410\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nOther income (expense)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nDividend/interest income\n \n150\n \n \n \n641\n \n \n \n511\n \n \n \n1,050\n \n\n\nInterest and finance expense\n \n(927\n)\n \n \n(914\n)\n \n \n(1,891\n)\n \n \n(1,072\n)\n\n\nChange in fair value of warrant liability\n \n(4\n)\n \n \n324\n \n \n \n214\n \n \n \n647\n \n\n\nChange in fair value of derivative liability\n \n256\n \n \n \n500\n \n \n \n1,314\n \n \n \n1,012\n \n\n\nForeign exchange gain/ (loss)\n \n74\n \n \n \n(42\n)\n \n \n(72\n)\n \n \n(34\n)\n\n\nLoss on extinguishment of debt\n \n(624\n)\n \n \n-\n \n \n \n(624\n)\n \n \n-\n \n\n\nLoss on disposal of fixed assets\n \n(171\n)\n \n \n-\n \n \n \n(171\n)\n \n \n-\n \n\n\nEstimated liability for contingent loss\n \n-\n \n \n \n(400\n)\n \n \n-\n \n \n \n(598\n)\n\n\nOther income / (expense)\n \n49\n \n \n \n-\n \n \n \n48\n \n \n \n(77\n)\n\n\nTotal other income/ (expense)\n \n(1,196\n)\n \n \n109\n \n \n \n(671\n)\n \n \n929\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss before income taxes\n$\n(14,029\n)\n \n$\n(17,426\n)\n \n$\n(27,083\n)\n \n$\n(32,481\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nProvision for income taxes\n \n-\n \n \n \n-\n \n \n \n-\n \n \n \n-\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss\n$\n(14,029\n)\n \n$\n(17,426\n)\n \n$\n(27,083\n)\n \n$\n(32,481\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nLess : net loss attributable to non-controlling interest\n \n(671\n)\n \n \n(1,205\n)\n \n \n(1,525\n)\n \n \n(2,165\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet loss attributable to Beyond Air, Inc.\n \n(13,358\n)\n \n \n(16,220\n)\n \n \n(25,559\n)\n \n \n(30,315\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nForeign currency translation loss\n \n(79\n)\n \n \n(35\n)\n \n \n24\n \n \n \n(9\n)\n\n\nComprehensive loss attributable to Beyond Air, Inc.\n$\n(13,438\n)\n \n$\n(16,255\n)\n \n$\n(25,535\n)\n \n$\n(30,325\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nNet basic and diluted loss per share attributable to Beyond Air, Inc.\n$\n(0.28\n)\n \n$\n(0.51\n)\n \n$\n(0.55\n)\n \n$\n(0.96\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\nWeighted average number of shares, outstanding, basic and diluted\n \n47,118,535\n \n \n \n31,800,492\n \n \n \n46,513,005\n \n \n \n31,592,880","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482765512"}